Salvianolic Acids: Potential Source of Natural Drugs for the Treatment of Fibrosis Disease and Cancer - PubMed (original) (raw)

Review

Salvianolic Acids: Potential Source of Natural Drugs for the Treatment of Fibrosis Disease and Cancer

Lunkun Ma et al. Front Pharmacol. 2019.

Abstract

Salvianolic acids, the most effective and abundant compounds extracted from Salvia miltiorrhiza (Danshen), are well known for its good anti-oxidative activity. Danshen has been extensively used as a traditional medicine to treat cardiovascular-related diseases in China and other Asian countries for hundreds of years. Recently, more and more studies have demonstrated that salvianolic acids also have a good effect on the alleviation of fibrosis disease and the treatment of cancer. In vivo and in vitro experiments have demonstrated that salvianolic acids can modulate signal transduction within fibroblasts and cancer cells. It is discovered that the cancer treatment of salvianolic acids is not only because salvianolic acids promote the apoptosis of cancer cells, but also due to the inhibition of cancer-associated epithelial-mesenchymal transition processes. In this article, we review a variety of studies focusing on the comprehensive roles of salvianolic acids in the treatment of fibrosis disease and cancer. These perspectives on the therapeutic potential of salvianolic acids highlight the importance of these compounds, which could be the novel and attractive drugs for fibrosis disease and cancer.

Keywords: Salvia miltiorrhiza; compounds; epithelial-mesenchymal transition; fibroblasts; traditional medicine.

PubMed Disclaimer

Figures

FIGURE 1

FIGURE 1

Chemical structure of Salvianolic acids. (A) Salvianolic acid A; (B) Salvianolic acid B; (C) Salvianolic acid C; and (D) Salvianolic acid D.

FIGURE 2

FIGURE 2

Schematic model of the multiple mechanisms of Salvianolic acids for liver fibrosis treatment.

FIGURE 3

FIGURE 3

Schematic model of the multiple mechanisms of Salvianolic acids for pulmonary fibrosis treatment.

FIGURE 4

FIGURE 4

Inhibition of Salvianolic acid B on EMT process.

Similar articles

Cited by

References

    1. Aubry M. C., Myers J. L., Douglas W. W., Tazelaar H. D., Stephens T. L. W., Hartman T. E., et al. (2002). Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin. Proc. 77 763–770. 10.4065/77.8.763 - DOI - PubMed
    1. Bottinger E. P. (2007). TGF-beta in renal injury and disease. Semin. Nephrol. 27 309–320. 10.1016/j.semnephrol.2007.02.009 - DOI - PubMed
    1. Brabletz T. (2012). EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 22 699–701. 10.1016/j.ccr.2012.11.009 - DOI - PubMed
    1. Cai J., Chen S., Zhang W., Zheng X., Hu S., Pang C., et al. (2014). Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway. Phytomedicine 21 1725–1732. 10.1016/j.phymed.2014.08.007 - DOI - PubMed
    1. Chen F. Y., Bi L., Qian L., Gao J., Jiang Y. C., Chen W. P. (2016). Identification of multidrug resistance gene MDR1 associated microRNA of salvianolic acid A reversal in lung cancer. China J. Chinese Mater. Med. 41 3279–3284. 10.4268/cjcmm20161726 - DOI - PubMed

Publication types

LinkOut - more resources